Equities research analysts expect CRISPR Therapeutics AG (NASDAQ:CRSP) to announce ($1.23) earnings per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for CRISPR Therapeutics' earnings, with estimates ranging from ($1.38) to ($0.70). CRISPR Therapeutics reported earnings of $0.51 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 341.2%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, February 10th.

According to Zacks, analysts expect that CRISPR Therapeutics will report full-year earnings of ($4.92) per share for the current fiscal year, with EPS estimates ranging from ($5.15) to ($4.44). For the next financial year, analysts anticipate that the business will report earnings of ($5.07) per share, with EPS estimates ranging from ($6.38) to ($3.67). Zacks Investment Research's earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for CRISPR Therapeutics.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, November 2nd. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.18) by ($0.14). The firm had revenue of $0.15 million during the quarter, compared to analysts' expectations of $2.22 million. CRISPR Therapeutics had a negative return on equity of 20.72% and a negative net margin of 273.10%. The company's revenue was down 99.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.40 earnings per share.

A number of equities research analysts have issued reports on the stock. Piper Sandler cut their price objective on shares of CRISPR Therapeutics from $128.00 to $107.00 and set an "overweight" rating for the company in a report on Thursday, October 29th. Chardan Capital increased their price objective on shares of CRISPR Therapeutics from $100.00 to $110.00 and gave the company a "buy" rating in a report on Thursday, October 22nd. SunTrust Banks assumed coverage on shares of CRISPR Therapeutics in a report on Tuesday, July 14th. They set a "buy" rating and a $140.00 price objective for the company. Stifel Nicolaus increased their price objective on shares of CRISPR Therapeutics from $75.00 to $93.00 and gave the company a "hold" rating in a report on Wednesday, October 21st. Finally, William Blair reiterated a "buy" rating on shares of CRISPR Therapeutics in a research report on Tuesday, July 28th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have issued a buy rating to the stock. CRISPR Therapeutics has an average rating of "Buy" and an average target price of $99.56.

In related news, Director Bradley J. Phd Bolzon sold 60,000 shares of the firm's stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $92.51, for a total value of $5,550,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bradley J. Phd Bolzon sold 3,035 shares of the firm's stock in a transaction on Friday, September 18th. The stock was sold at an average price of $86.87, for a total value of $263,650.45. Following the completion of the sale, the director now owns 7,391 shares of the company's stock, valued at $642,056.17. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 133,000 shares of company stock valued at $12,064,743. 21.40% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in CRSP. Geode Capital Management LLC increased its stake in CRISPR Therapeutics by 9.5% in the first quarter. Geode Capital Management LLC now owns 42,950 shares of the company's stock worth $1,821,000 after purchasing an additional 3,716 shares during the period. Morgan Stanley increased its stake in CRISPR Therapeutics by 233.6% in the first quarter. Morgan Stanley now owns 851,519 shares of the company's stock worth $36,113,000 after purchasing an additional 596,255 shares during the period. State Street Corp increased its stake in CRISPR Therapeutics by 48.2% in the first quarter. State Street Corp now owns 71,211 shares of the company's stock worth $3,020,000 after purchasing an additional 23,159 shares during the period. Carroll Financial Associates Inc. increased its stake in CRISPR Therapeutics by 100.0% in the second quarter. Carroll Financial Associates Inc. now owns 900 shares of the company's stock worth $66,000 after purchasing an additional 450 shares during the period. Finally, McGuire Investment Group LLC purchased a new stake in CRISPR Therapeutics in the second quarter worth $239,000. Institutional investors and hedge funds own 55.29% of the company's stock.

Shares of CRSP opened at $99.65 on Tuesday. CRISPR Therapeutics has a 1 year low of $32.30 and a 1 year high of $111.90. The company has a 50 day simple moving average of $93.27 and a two-hundred day simple moving average of $80.22. The firm has a market cap of $7.04 billion, a P/E ratio of -30.57 and a beta of 2.26.

About CRISPR Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.

Recommended Story: What is a Reverse Stock Split?

Get a free copy of the Zacks research report on CRISPR Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CRISPR Therapeutics (NASDAQ:CRSP)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

7 Boring Stocks That Are Winners

Some stocks don’t get much attention during bull markets. They can be too boring for a growth portfolio. But when the market is going through a period of volatility and uncertainty, these tried-and-true performers have a way of making their way back to popularity.

And there are good reasons for this. First, many of these boring stocks pay dividends. This means that the company will reward shareholders simply for holding on to its stock. Dividend stocks aren’t designed to make you rich quickly. However, they are designed to offer investors an amount of predictability. And we could all use a little bit of that right now.

And predictable stocks can also help investors manage risk. It can be fun to invest in speculative stocks. But they include a risk premium. When these stocks go up (as they sometimes do), they usually have a return that exceeds the broader market. But when they go down (and usually do), they usually go down more than the broader market.

But “boring” stocks tend to move closer to the broader market. If you want an analogy from current events, these stocks flatten the curve. They won’t soar as high as riskier stocks, but they won’t sink as low either. And right now, preserving capital should be the number one item on every investor’s checklist.

With that in mind, we’ve created this special presentation to highlight 7 conservative stocks that can help investors win this moment in time. Many of them pay dividends; some do not. But they all have solid fundamental reasons to own them now.

View the "7 Boring Stocks That Are Winners".



Source link